Study of the noncovalent interactions of ginsenosides and amyloid‐β‐peptide by CSI‐MS and molecular docking

Zhou, Yanan; Su, Chen; Qiao, Jie; Cui, Yanyun; Chang, Yuan; Ouyang, Jin

doi:10.1002/jms.4463

Cited by 6 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Amyloid β (Aβ) peptide plays an important role in AD. Zhou et al reported that Re may interfere with AD progression by affecting the Aβ peptide ( Zhou et al, 2020 ). Oral administration of Re (25 mg/kg, i.g.…”

Section: Pharmacological Effects Of Re On Nervous Diseasesmentioning

confidence: 99%

Pharmacological Properties of Ginsenoside Re

et al. 2022

View full text Add to dashboard Cite

Ginsenoside Re is a protopanaxatriol-type saponin extracted from the berry, leaf, stem, flower bud, and root of Panax ginseng. In recent years, ginsenoside Re (Re) has been attracting attention as a dietary phytochemical. In this review, studies on Re were compiled by searching a combination of keywords, namely “pharmacology,” “pharmacokinetics,” and “toxicology,” in the Google Scholar, NCBI, PubMed, and Web of Science databases. The aim of this review was to provide an exhaustive overview of the pharmacological activities, pharmacokinetics, and toxicity of Re, focusing on clinical evidence that has shown effectiveness in specific diseases, such as diabetes mellitus, nervous system diseases, inflammation, cardiovascular disease, and cancer. Re is also known to eliminate virus, enhance the immune response, improve osteoporosis, improve skin barrier function, enhance intracellular anti-oxidant actions, regulate cholesterol metabolism, alleviate allergic responses, increase sperm motility, reduce erectile dysfunction, promote cyclic growth of hair follicles, and reduce gastrointestinal motility dysfunction. Furthermore, this review provides data on pharmacokinetic parameters and toxicological factors to examine the safety profile of Re. Such data will provide a theoretical basis and reference for Re-related studies and future applications.

show abstract

Section: Pharmacological Effects Of Re On Nervous Diseasesmentioning

confidence: 99%

Pharmacological Properties of Ginsenoside Re

et al. 2022

View full text Add to dashboard Cite

show abstract

“…A variant of ESI‐MS, called cold spray ionisation mass spectrometry (CSI‐MS) is an alternative method. It proved to be a milder and less destructive method, advantageous when studying non‐covalent drug‐protein stoichiometries, and thus could be a more appropriate approach for many aspects of Aβ therapeutics research (Jiang et al, 2019; Zhou et al, 2020).…”

Section: Tools For Analysismentioning

confidence: 99%

Biological and methodological complexities of beta‐amyloid peptide: Implications for Alzheimer’s disease research

Matuszyk

Garwood

Ferraiuolo

et al. 2021

Journal of Neurochemistry

View full text Add to dashboard Cite

Although controversial, the amyloid cascade hypothesis remains central to the Alzheimer's disease (AD) field and posits amyloid‐beta (Aβ) as the central factor initiating disease onset. In recent years, there has been an increase in emphasis on studying the role of low molecular weight aggregates, such as oligomers, which are suggested to be more neurotoxic than fibrillary Aβ. Other Aβ isoforms, such as truncated Aβ, have also been implicated in disease. However, developing a clear understanding of AD pathogenesis has been hampered by the complexity of Aβ biochemistry in vitro and in vivo. This review explores factors contributing to the lack of consistency in experimental approaches taken to model Aβ aggregation and toxicity and provides an overview of the different techniques available to analyse Aβ, such as electron and atomic force microscopy, nuclear magnetic resonance spectroscopy, dye‐based assays, size exclusion chromatography, mass spectrometry and SDS‐PAGE. The review also explores how different types of Aβ can influence Aβ aggregation and toxicity, leading to variation in experimental outcomes, further highlighting the need for standardisation in Aβ preparations and methods used in current research.

show abstract

In vitro, in vivo, and in silico evidence for the use of plant pigments betalains as potential nutraceuticals against Alzheimer's disease

Martínez‐Rodríguez,

Henarejos‐Escudero,

Hernández‐García

et al. 2024

Food Frontiers

View full text Add to dashboard Cite

Anti‐amyloidogenic properties of plant pigments betalains as potential nutraceuticals against Alzheimer's disease have been screened using 24 pure molecules. Twenty‐two betalains reduced amyloid aggregation in vitro, eight of them up to 100%, with IC50 values in the micromolar range. Atomic force and transmission electron microscopy images showed the typical fibrils associated with Alzheimer's disease and how betalains avoid its formation. Neuroprotection after ingestion was supported by in vivo experiments with Caenorhabditis elegans. Indoline‐betacyanin was the most effective molecule by significantly improving the chemotactic behavior of the CL2355 strain, a model of Alzheimer's disease. Furthermore, in‐depth molecular docking analyses revealed that the pigments interact with the N‐terminal region of the amyloid peptide. This work is the most comprehensive study in the field and provides in vitro, in vivo, and in silico evidence for the use of betalains as nutraceuticals of relevance in the prevention of Alzheimer's disease.

show abstract

Study of the noncovalent interactions of ginsenosides and amyloid‐β‐peptide by CSI‐MS and molecular docking

Cited by 6 publications

References 31 publications

Pharmacological Properties of Ginsenoside Re

Pharmacological Properties of Ginsenoside Re

Biological and methodological complexities of beta‐amyloid peptide: Implications for Alzheimer’s disease research

In vitro, in vivo, and in silico evidence for the use of plant pigments betalains as potential nutraceuticals against Alzheimer's disease

Contact Info

Product

Resources

About